Abstract
Substantial advances have been made in the systemic treatment of breast cancer with residual disease following neoadjuvant therapy. We reviewed recent and ongoing studies informing the standard clinical management of residual disease by subtype: HER2+, TNBC, and HR+/HER2-, as well as strategies for BRCA+ disease. We conclude with a discussion of ongoing clinical trials and current controversies regarding the treatment of residual disease in breast cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 18-25 |
| Number of pages | 8 |
| Journal | Journal of surgical oncology |
| Volume | 129 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2024 |
Keywords
- adjuvant therapy
- breast cancer
- postneoadjuvant
- residual cancer burden
- residual disease
ASJC Scopus subject areas
- Surgery
- Oncology
